Table 1.
The scenarios modeled1
| Scenario (S#) | Class | # shRNA | Efficacy (%) | HSC+ (%) | Fitness (%) |
|---|---|---|---|---|---|
| S0 | Untreated | ||||
| S1 | I & II | 6 | 80n | 20 | 99 |
| S2 | I & II | 4 | 80n | 20 | 99 |
| S3 | I & II | 2 | 80n | 20 | 99 |
| S4 | I & II | 6 | 60n | 20 | 99 |
| S5 | I & II | 6 | 80n | 1 | 99 |
| S6 | I & II | 2 | 80n | 20 | 50 |
| S7 | I & II | 2 | 80n | 1 | 50 |
| S8 | I & II | 6 | 80n | 20 | 90 |
| S9 | I & II | 6 | 80n | 20 | 50 |
| S10 | I & II | 2 | 80n | 20 | 90 |
| S11 | II only | 6 | 80n | 20 | 99 |
1Twelve scenarios (S#) varied in the number of shRNAs considered (6, 4 and 2 shRNAs), the efficacy of each shRNA (60 or 80%), the proportion of hematopoietic stem cells transduced with the gene therapeutic (HSC+; 20 or 1%), viral fitness (99, 90, or 50%), and the class of treatment (Class I and II). The untreated control (S0) contained only UNTx cells exposed to HIV.